Inactivated SARS–CoV–2 Vaccine Inducing Acute Transverse Myelitis and Hypercoagulable State: A Case Report

Lisda Amalia

Abstract


Introduction: Global pandemic of Coronavirus disease 2019 (COVID-19) have been developed with a respiratory infection as main symptom and vaccines had been proven against SARS-CoV-2 infection. We would like to present acute transverse myelitis with hypercoagulable condition case, after receiving the inactive SARS-CoV-2 vaccine (SinoVac). Case Presentation: This is a case from a 20-year-old male with acute onset of flaccid paraplegia, hyporeflexia, loss of sensation below 5th thoracic level, loss of autonomic function, and a positive Babinski sign bilaterally on 7 days after receiving SARS-CoV-2 vaccine. From lumbar puncture examination, we found elevated liquor cerebrospinal protein with mononuclear cell predominantly and elevated d-dimer and also decreased fibrinogen levels from laboratory examination. From Magnetic Resonance Imaging (MRI) showed hyperintensity at the 5th until 9th thoracal level. He improved motoric strength of the lower limb (walking without assistance), numbness and pain, urine and fecal retention after receiving methylprednisolone for 3 days. Conclusion: Acute transverse myelitis with hypercoagulable state was a rare case associated with COVID-19 vaccination, but clinician should be aware for early detection and giving proper treatment.

Keywords


Acute transverse myelitis, hypercoagulable state, inactivated SARS-CoV-2 vaccine

Full Text:

PDF

References


Roman GC, Gracia, F, Torres A, Palacios A, Gracia K, Harris D. Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-Associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 n CoV-19 vaccine (AZD1222). Front. Immunol. 2021, 12, 653786.

Samudralwar RD, Das RR, Nath A. ANA Investigates: neurological complications of COVID-19 vaccines. Ann. Neurol. 2021, 89, 856–57.

Notghi AA, Atley J, Silva M. Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination. Clin. Med. 2021, 21, e535–e538.

Khan E, Shrestha AK, Colantonio MA Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: A case report and review of literature. J. Neurol. 2021, 5, 1–12.

Tahir N, Koorapati G, Prasad S, Jeelani HM, Sherchan R, Shrestha J, et al. SARS-CoV-2 vaccination-induced transverse myelitis. Cureus. 2021;13(7):1-5. Doi: 10.7759/cureus.16624.

Erdem NS, Demirci S, Özel T, Mamadova K, Karaali K, Çelik HT, et al. Acute transverse myelitis after inactivated COVID-19 vaccine. Ideggyogy. Szle. 2021, (74-8) 273–76. Doi: https://doi.org/10.18071/isz.74.0273.

Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J. Neuroimmunol. 2021, 358:1-6. Doi; 10.1016/j.jneuroim.2021.577606.

Helmchen C, Buttler GM, Markewitz R, Hummel K, Wiendl H, Boppel T. Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2. J. Neurol. 2021;269(1): 48-54. Doi: 10.1007/ s00415-021-10647-x.

Malhotra HS, Gupta P, Prabhu V, Garg RK, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. QJM. 2021;114(8): 591-93. Doi: 10.1093/qjmed/hcab069.

Vegezzi E, Ravaglia S, Buongarzone G, Bini P, Diamanti L, Gastaldi M, et al. Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association? J. Neuroimmunol. 2021, 359, 577686. Doi; 10.1016/j.jneuroim.2021.577686.

Taiwan Centers for Disease Control (CDC). Vaccine adverse event reporting system (VAERS). Available online: https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637590432301286539&type=2&cid=37080

Ahmad SA, Salih KH, Ahmed SF, Kakamad FH, Salh AM, Hassan MN, et al. Post COVID-19 transverse myelitis; a case report with review of literature. Ann. Med. Surg. 2021; 69:1-3. Doi: 10.1016/j.amsu.2021.102749.

Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. Transverse Myelitis: Pathogenesis, diagnosis and treatment.Front. Biosci. 2004, 9, 1483–99. Doi: 10.2741/1351

Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam, JS, Snape MD, Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data. Lancet 2021, 397(10289):2043-46. Doi: 10.1016/S0140-6736(21)01115-6.

Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat. Commun. 2021;12(1):2893. Doi: 10.1038/s41467-021-23173-1

Borobia AM, Carcas AJ, Pérez MT, Castaño L, Jesús BM, García-Pérez J, et al. Reactogenicity and immunogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1s: initial results of a randomised, adaptive, Phase 2 Trial (CombiVacS). 2021. Available online: https://ssrn.com/abstract=3854768.

Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N. Engl. J. Med. 2021;385(11):1049–051. Doi: 10.1056/NEJMc2110716

Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 2021;27(9): 1525–29. Doi: 10.1038/s41591-021-01449-9.

Amalia L. Hypercoagulable state induced spinal cord stroke after Coronavirus Disease 19 infection. J Blood Med. Dovepress. 2021;12:1057-1060. Doi: 10.2147/JBM.S329449.




DOI: https://doi.org/10.24244/jni.v14i1.631

Refbacks

  • There are currently no refbacks.


                                    

 

JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License